Osteoarthritis and Bone Disorders News

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, according to an industry press release.

Patients with osteoarthritis, but not immune-related arthritis, demonstrate increased odds for developing overactive bladder vs. those without, according to data spanning 15 years published in Science Reports.

Multivitamin and cocoa extract supplements do not protect against clinical fractures for older adults, according to data published in the Journal of Bone and Mineral Research.

Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the medication through a new Novo Nordisk direct-to-consumer program.

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, according to a press release from Celltrion.

Women with osteoporosis have at least a 50% chance of reaching their target bone mineral density at 3 years if they have a BMD T-score of at least –2.8 at the total hip or –3.1 at the lumbar spine at baseline, according to study findings.

Published results showed patients with obesity who took anti-obesity medications and had postoperative weight loss within 1 year after total joint arthroplasty may be at significantly decreased risk for revision at 5 and 10 years.

The FDA has approved two new biosimilars of denosumab to treat osteoporosis, increase bone mass, prevent skeletal-related events for people with multiple myeloma and other indications, Samsung Bioepis announced.

Surrogate measures of insulin resistance, based on the triglyceride-glucose index, can be used to predict the development of osteoarthritis, according to data published in Scientific Reports.